In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Warner-Lambert and Sankyo form 50/50 US joint venture

Executive Summary

Warner-Lambert and Sankyo formed a 50/50 US joint venture Sankyo/Parke-Davis to co-promote two products: Sankyo's troglitazone (diabetes) and WL's Accupril (ACE inhibitor quinapril), replacing their 1991 deal for troglitazone.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • Joint Venture
    • R&D and Marketing (Licensing)

Related Companies